Vertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a treatment option for up to 90% of patients with the genetic disease cystic fibrosis.
The fixed-dose triple-combination therapy, dubbed ‘vanza triple’, is set to build on the success of Vertex’s top-selling combination of elexacaftor, tezacaftor and ivacaftor (Trikafta ...
FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 newly eligible U.S. patients. Suzetrigine for acute pain aligns with NOPAIN Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback